Metly

MetlyMetly
Metly

Metly

Metly empowers pharma companies to accelerate product launches through intelligent opportunity detection and partner matching.

DR 62021Active10New York, United States
Rate

About

Metly provides pharma intelligence that runs continuously in the background, aggregating data and automating intelligence workflows. Its core product helps pharmaceutical teams discover opportunities, monitor competitors, and automatically update deliverables by searching regulatory filings, clinical databases, and partnership signals. Metly serves pharmaceutical companies by putting their intelligence function on autopilot so teams can focus on what matters.
Frequently asked

What does Metly do?

Metly provides pharma intelligence that runs continuously in the background, aggregating data and automating intelligence workflows. Its core product helps pharmaceutical teams discover opportunities, monitor competitors, and automatically update deliverables by searching regulatory filings, clinical databases, and partnership signals. Metly serves pharmaceutical companies by putting their intelligence function on autopilot so teams can focus on what matters.

What is Metly's revenue?

StartupHub estimates Metly's annual revenue at $1.5M (range $865K to $2.4M, 64% confidence), based on comparable companies in the sector.

What is Metly's valuation?

StartupHub estimates Metly's effective valuation at $10.3M (range $6.7M to $16.1M, 18% confidence), based on comparable companies in the sector.

How much funding has Metly raised?

Metly has raised a total of $3M in funding. The most recent round on record is Pre-Seed.

Where is Metly headquartered?

Metly is headquartered in New York, United States.

When was Metly founded?

Metly was founded in 2021.

What industry does Metly operate in?

Metly operates in Biotech, MedTech, HealthTech, Drug Discovery, Clinical Trials, Enterprise Software.

How many employees does Metly have?

Metly has approximately 10 people on record.

HEADCOUNT
10
DOMAIN RATING
6
Comments

No comments yet. Be the first to share your take.